Immunogenicity of a five-microgram dose of hepatitis B vaccine
โ Scribed by George Papaevangelou; Anastasia Roumeliotou-Karayannis; Charalambos Vissoulis; Steven-Clive Richardson; Saul Krugman
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 291 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
โฆ Synopsis
The immunogenicity of a 5-micrograms dose of vaccine (H-B-Vax, MSD) was evaluated in 50 young adults (17-19 years). Results were compared to our previous studies using similarly prepared vaccines using 20 micrograms and 10 micrograms per dose with the same trial protocol in a comparable population. Seroconversion rates for the 5-micrograms doses of vaccine were 80% after the first dose and 98% after the second dose. The remaining participants did not develop anti-HBs in the course of the trial. These results are not significantly different from those observed in the 10-micrograms and 20-micrograms studies. The increase of anti-HBs titers was slower for the 5-micrograms group. High geometric mean titers were observed after booster vaccination, but lower for the 5 micrograms (3,591 mIU/ml) than for 10 micrograms (9,277 mIU/ml) and 20 micrograms (12,975 mIU/ml) doses. It is concluded that 5-micrograms dose of the vaccine is effectively immunogenic for young adults.
๐ SIMILAR VOLUMES
A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.
The immunogenic effect of hepatitis B vaccine was evaluated in 183 seronegative infants from Senegal. Seventy-two seronegative infants received two 5-micrograms doses of vaccine at a two-month interval and 111 seronegative infants received three 5-micrograms doses at one-month intervals. All the chi
Six hundred and fifty New Zealand children from 2-12 years of age were vaccinated three times with 2 mcg intramuscular (IM) doses of Merck Sharp and Dohme plasma-derived hepatitis B vaccine (H-B-Vax), at 0, 1, and 6 months, and tested 2-3 months later for antibody to hepatitis B surface antigen (ant
Horizontal transmission of hepatitis B virus (HBV) from illicit drug users to their contacts, including young children, can be prevented by active immunization against HBV. Yeast-recombinant hepatitis B vaccines are now available for this purpose, but their potential efficacy in such high-risk conta